Eli Lilly reported asecond-quarter profit that was boosted by higher sales for the antidepressant Cymbalta, which helped trim losses from generic competition to its former top-seller, Zyprexa.

Eli Lilly and Company — the tenth largest pharmaceutical company in the world — is to make its €1 billion Kinsale facility the main launch site for all new products.

Eli Lilly & chief executive John Lechleiter said rising sales of the antidepressant Cymbalta and animal drugs stemmed losses from generic competition, helping the company’s earnings beat estimates.